ANI PHARMACEUTICALS Reports 57.3% Increase in Total Revenue for Q3 Fiscal Year 2023
November 22, 2023
☀️Earnings Overview
For the third quarter of fiscal year 2023, ANI PHARMACEUTICALS ($NASDAQ:ANIP) announced total revenue of USD 131.8 million, a 57.3% increase from the same quarter of the previous year. Net income amounted to USD 9.9 million, versus a net loss of -8.6 million the prior year.
Analysis
GoodWhale has conducted an analysis of ANI PHARMACEUTICALS‘s wellbeing. According to the Star Chart, ANI PHARMACEUTICALS has an intermediate health score of 5/10 with regard to its cashflows and debt, meaning that it might be able to sustain future operations in times of crisis. Further analysis reveals that ANI PHARMACEUTICALS is strong in terms of growth and profitability, and medium in terms of assets. However, it is weak in terms of dividend. Based on this data, ANI PHARMACEUTICALS can be classified as a ‘gorilla’ company, one that has achieved stable and high revenue or earning growth due to its strong competitive advantage. Investors who are looking for companies that have a strong competitive advantage and are able to achieve consistent growth may find ANI PHARMACEUTICALS appealing. Those looking for high returns on their investments may also be attracted to the company’s strengths in profitability and growth. Furthermore, due to the intermediate health score, it might be a good option for investors who want to minimize the risk associated with their investments. More…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Ani Pharmaceuticals. More…
| Total Revenues | Net Income | Net Margin |
| 449.39 | 11.76 | 3.6% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Ani Pharmaceuticals. More…
| Operations | Investing | Financing |
| 69.82 | -16.87 | 78.85 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Ani Pharmaceuticals. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 889.91 | 435.2 | 22.3 |
Key Ratios Snapshot
Some of the financial key ratios for Ani Pharmaceuticals are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 31.2% | -15.0% | 9.3% |
| FCF Margin | ROE | ROA |
| 11.8% | 5.9% | 2.9% |
Peers
The company’s products are available in a wide range of therapeutic areas, including cardiovascular, central nervous system, endocrine, gastrointestinal, and infectious diseases. ANI also offers a portfolio of branded products, which are marketed under the names ANI-Pulse and ANI-Q. The company’s competitors include Theratechnologies Inc, Cipher Pharmaceuticals Inc, Avadel Pharmaceuticals PLC.
– Theratechnologies Inc ($TSX:TH)
The company’s market cap is 248.32M as of 2022 and its ROE is 182.08%. The company is engaged in the research, development and commercialization of therapeutic solutions for people living with rare diseases. The company’s products include Tremegus, a treatment for hemophilia A; Trelegy, a treatment for COPD; and Tevagus, a treatment for Huntington’s disease.
– Cipher Pharmaceuticals Inc ($TSX:CPH)
Cipher Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of therapeutics for the treatment of dermatologic and neuropsychiatric diseases in Canada and the United States. The company was founded by Robert Tessier and Shawn Patrick O’Neil in December 1999 and is headquartered in Mississauga, Canada.
– Avadel Pharmaceuticals PLC ($NASDAQ:AVDL)
Adaval Pharmaceuticals PLC is a publicly traded company with a market capitalization of 354.4 million as of 2022. The company has a return on equity of -245.41%. Adaval is a pharmaceutical company that focuses on the development and commercialization of novel therapeutics for the treatment of central nervous system disorders.
Summary
ANI Pharmaceuticals experienced strong financial performance in the third quarter of its fiscal year 2023, with total revenue increasing 57.3% year-over-year to USD 131.8 million, and net income improving from a loss of -8.6 million to a profit of USD 9.9 million. Despite this impressive performance, investors were seemingly unimpressed, as the stock price moved down the same day. Moving forward, investors should keep an eye on ANI Pharmaceuticals’ financial performance and analyze whether the company can continue its upward trajectory.
Related Posts
Recent Posts
